bpc-157 anti-inflammatory Uncovered BPC-157 has already hit the

These new codes that were effective April 1, 2025, were assigned to comment indicator NP in Addendum B to the CY 2026 OPPS/APC proposed rule to indicate that the codes are assigned to an interim APC assignment and comments would be accepted on their interim APC assignments

Products are not evaluated by the FDA or any regulatory authority for human use

We are not yet offering AOD 9604 to patients

BPC-157s only human studies were early-phase trials for inflammatory bowel disease

AOD-9604, thanks to its mechanism (lipolysis directly from adipose tissue without effect on muscle cells), may help steer the weight reduction toward the fat component